Larotrectinib

Solid Neoplasm

Children's Oncology GroupSmall moleculePhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 95/ 100

Competitive context

7 Active assets in the Solid Neoplasm cohort.

Asset / Sponsor	Phase	Rating
Namenda NRG Oncology	Phase 3	BB
CIS-DIAMMINEDICHLOROPLATINUM II Emory University	Phase 1	CCC
Bms-907351 National Cancer Institute (NCI)	Phase 2	CCC
Carboplatin Emory University	Phase 1	CCC
Veliparib National Cancer Institute (NCI)	Phase 1	CCC

View all 24 →

Same molecule, other indications

Larotrectinib is also rated in:

NTRK fusion positive cancerDormant

BB

Indicative ·

65 / 100

non-Hodgkin lymphomaDormant

CCC

Indicative ·

53 / 100

Locally Advanced Malignant Solid NeoplasmDormant

CCC

Indicative ·

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.